01 May 2004
Serum cathepsin B activity during regression of Morris hepatoma 5123 D
Artur Fedorowski, Andrzej Steciwko, Jerzy RabczyńskiMed Sci Monit 2004; 10(5): BR144-150 :: ID: 11644
Abstract
Background:Serum cathepsin B activity has been considered a potential marker of tumor progression. We previously demonstrated that low-frequency electromagnetic stimulation (LF EMS), called bioresonance therapy (BRT), may both accelerate and inhibit the growth of transplantable hepatoma (Morris type 5123D), including total tumor regression. The aim of this study was to assess serum cathepsin activity during tumor progression and regression.Material/Methods: Of 60 female rats inoculated with Morris hepatoma cells, 45 were treated with BRT, and the remaining 15 were left without treatment. Fifteen rats without inoculated tumors served as controls. Serum cathepsin B activity was determined, tumor volumes were measured, and histological examinations of the tumor tissues were performed.Results: Of the 45 BRT-treated rats, tumor regression was observed in 31 rats, and serum cathepsin activity was analyzed in these rats. In all non-treated rats, tumor progression was observed. Serum cathepsin B activity was significantly higher in both the BRT-treated group (27.8±4.1 U/I,p<0.01) and the tumor-bearing group (19.9±2.5 U/l, p<0.05), as compared to the controls (13.3±3.4U/l).
Conclusions: Cathepsin B may play an important role, not only in tumor expansion, but also during the processes of cancer cell death and resorption. High circulating levels may thus correspond to effective therapeutic response in the course of antitumor treatment.
Keywords: Cathepsin B - blood, Cell Death, Cell Division, Disease Progression, Electromagnetics, Liver Neoplasms, Experimental, Necrosis, Neoplasm Transplantation, Tumor Markers, Biological, Cathepsin B - blood, Cell Death, Cell Division, Disease Progression, Electromagnetic Phenomena, Liver Neoplasms, Experimental, Necrosis, Neoplasm Transplantation, Tumor Markers, Biological
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952